PML protein expression in hereditary and sporadic breast cancer

Neoplasma

Volumn 54, Issue 4, 2007, Pages 263-268

  Plevova P ^a,b   Bouchal, J ^a   Fiuraskova M ^a   Foretova L ^c   Navratilova M ^c   Zapletalova J ^a   Curik R ^b   Kubala, O ^b   Prokop, J ^b   Kolar Z ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

BRCA1 gene; BRCA2 gene; Breast cancer; PML protein

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROMYELOCYTIC LEUKEMIA PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; NUCLEAR PROTEIN; PML PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ARTICLE; BREAST CANCER; DISEASE MARKER; DOWN REGULATION; FAMILIAL CANCER; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; ONCOGENE; PROTEIN EXPRESSION; BREAST TUMOR; CELL NUCLEUS; COLLOID CARCINOMA; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; LUNG CARCINOMA; METABOLISM; MUTATION; PAGET NIPPLE DISEASE; PATHOLOGY;

ADENOCARCINOMA, MUCINOUS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL NUCLEUS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; ZINC FINGERS;

EID: 35448976497     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. SALOMONI P & PANDOLFI PP. The role of PML in tumor suppression. Cell 2002; 108: 165-170.
2. JENSEN K, SHIELS C, FREEMONT PS. The PML protein isoforms and the RBCC/TRIM motif. Oncogene 2001; 20: 7223-7233.
3. MAUL GG, YU E, ISHOV AM, et al. Nuclear domain 10 (ND10) associated proteins are also present in nuclear bodies and redistribute to hundreds of nuclear sites after stress. J Cell Biochem 1995; 59: 498-513.
4. ZHONG S, SALOMONI P, PANDOLFI PP. The transcriptional role of PML and the nuclear body. Nat Cell Biol 2000; 2: E85-90.
5. NEGOREV D & MAUL GG. Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene 2001; 20: 7234-7242.
6. RAHMAN N & STRATTON MR. The genetics of breast cancer susceptibility. Annu Rev Genet 1998; 32: 95-121.
7. LAKHANI SRR, VAN DE VIJVER MJ, JACQUEMIER J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20: 2310-2318.
8. de BOCK GH, TOLLENAAR RA, PAPELARD H, et al. Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients. Br J Cancer 2001; 85: 1347-1350.
9. International Union Against Cancer (UICC): TNM classification of malignant tumours, 6th edition. Sobin LH ed. Wiley-Liss, 2002, New York.
10. GURRIERI C, CAPODIECI P, BERNARDI R, et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 2004; 96: 269-279.
11. OSIN P, GUSTERSON BA, PHILP E, et al. Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. Eur J Cancer 1998; 34: 1683-1686.
12. OSIN PP & LAKHANI SR. The pathology of familial breast cancer: Immunohistochemistry and molecular analysis. Breast Cancer Res 1999; 1: 36-40. (Pubitemid 32223534)
13. ROBSON M, RAJAN P, ROSEN PP, et al. BRCA-associated breast cancer: absence of a characteristic immunophenotype. Cancer Res 1998; 58: 1839-1842.
14. GAMBACORTA M, FLENGHI L, FAGIOLI M, et al. Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. Am J Pathol 1996; 149: 2023-2035.
15. CHAN JY, MENG CL, TO KF, et al. Differential expression of the suppressor PML and Ki-67 identifies three subtypes of human nasopharyngeal carcinoma. Eur J Cancer 2002; 38: 1600-1606.
16. KOKEN MH, LINARES-CRUZ G, QUIGNON F, et al. The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 1995; 10: 1315-1324.
17. YU E, LEE KW, LEE HJ. Expression of promyelocytic leukaemia protein in thyroid neoplasms. Histopathology 2000; 37: 302-308. (Pubitemid 30781583)
18. ZHANG H, MELAMED J, WEI P, et al. Concordant downregulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immun 2003; 3:2.
19. ZHANG P, CHIN W, CHOW LT, et al. Lack of expression for the suppressor PML in human small cell lung carcinoma. Int J Cancer 2000; 85: 599-605.
20. FLENGHI L, FAGIOLI M, TOMASSONI L, et al. Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of The PML proteins on activated macrophages, endothelial cells, and epithelia. Blood 1995; 85: 1871-1880.
21. FORETOVÁ L., MACHÁČKOVÁ E., NAVRÁTILOVÁ M. et al.: BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic. Hum Mutat 2004; 23: 397-398.